We are live on ! Find out more
LBA

Letko, Brosseau & Associates Portfolio holdings

AUM $6.77B
1-Year Est. Return 38.11%
This Fund
S&P 500
This Quarter Est. Return
-13.62%
1 Year Est. Return
+38.11%
3 Year Est. Return
+83.35%
5 Year Est. Return
+109.01%
10 Year Est. Return
+317.99%
AUM
$5.65B
AUM Growth
-$1.05B
Cap. Flow
-$60.9M
Cap. Flow %
-1.08%
Top 10 Hldgs %
34.59%
Holding
104
New
3
Increased
29
Reduced
51
Closed
4

Top Sells

Rank Stock Value
1
SU icon
Suncor Energy
SU
+$40.5M
2
TECK icon
Teck Resources
TECK
+$33.1M
3
GSK icon
GSK
GSK
+$29.2M
4
OVV icon
Ovintiv
OVV
+$25M
5
CVE.WS
Cenovus Energy Inc Warrants
CVE.WS
+$24.1M

Sector Composition

Rank Sector Weight
1 Financials 29.01%
2 Communication Services 17.69%
3 Energy 13.64%
4 Materials 10.84%
5 Technology 8.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BAP icon
76
Credicorp
BAP
$29.9B
$9.84M 0.17%
82,050
+25
+0% +$3.44K
PROF
77
Profound Medical
PROF
$212M
$8.89M 0.16%
1,255,025
-44,100
-3% -$349K
FLR icon
78
Fluor
FLR
$7.16B
$6.78M 0.12%
278,720
-17,200
-6% -$462K
PDS
79
Precision Drilling
PDS
$1.11B
$6.37M 0.11%
99,340
-12,000
-11% -$871K
YTRA icon
80
Yatra Online
YTRA
$72.3M
$4.81M 0.09%
2,138,020
SCHW
81
Charles Schwab
SCHW
$186B
$1.38M 0.02%
21,846
VT icon
82
Vanguard Total World Stock ETF
VT
$81B
$1.05M 0.02%
12,325
-2,175
-15% -$201K
ING icon
83
ING
ING
$105B
$915K 0.02%
92,236
-6,076
-6% -$62K
MET icon
84
MetLife
MET
$62.1B
$822K 0.01%
13,099
MYOV
85
DELISTED
Myovant Sciences Ltd.
MYOV
$786K 0.01%
63,204
ENB icon
86
Enbridge
ENB
$105B
$449K 0.01%
10,650
REPL icon
87
Replimune Group
REPL
$1.24B
$399K 0.01%
22,800
FTS icon
88
Fortis
FTS
$27.6B
$348K 0.01%
7,375
-166,000
-96% -$8.14M
OM icon
89
Outset Medical
OM
$59.2M
$334K 0.01%
1,500
DUK icon
90
Duke Energy
DUK
$92.8B
$332K 0.01%
3,100
NUE icon
91
Nucor
NUE
$57.8B
$303K 0.01%
2,900
KMB icon
92
Kimberly-Clark
KMB
$33B
$274K ﹤0.01%
2,025
CVE.WS
93
DELISTED
Cenovus Energy Inc Warrants
CVE.WS
$206K ﹤0.01%
15,196
-1,634,817
-99% -$24.1M
HRTX icon
94
Heron Therapeutics
HRTX
$59.9M
$160K ﹤0.01%
57,200
ATRA icon
95
Atara Biotherapeutics
ATRA
$92.8M
$122K ﹤0.01%
628
MDNA
96
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$116K ﹤0.01%
100,000
IMV
97
DELISTED
IMV Inc. Common Shares
IMV
$112K ﹤0.01%
17,000
ONCR
98
DELISTED
Oncorus, Inc.
ONCR
$75K ﹤0.01%
59,150
SPRO icon
99
Spero Therapeutics
SPRO
$66.4M
$55K ﹤0.01%
73,659
BCEL
100
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$32K ﹤0.01%
17,800

Similar funds

Letko, Brosseau & Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Letko, Brosseau & Associates held 104 positions worth $5.65B, down 16% from $6.7B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Letko, Brosseau & Associates's Q2 2022 filing shows 3 new, 29 increased, 51 reduced and 4 closed positions. Its largest new stake was Netflix: 860,000 shares worth $15M. The largest sale was Suncor Energy, an estimated $40.5M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, down from 29% a quarter earlier, followed by Communication Services and Energy.

  • Letko, Brosseau & Associates's largest Q2 2022 buy was Netflix: 860,000 shares worth $15M.
  • Letko, Brosseau & Associates added most to Manulife Financial in Q2 2022, an estimated $26.9M increase.
  • Letko, Brosseau & Associates's biggest Q2 2022 reduction was Suncor Energy, cutting an estimated $40.5M.
  • Letko, Brosseau & Associates fully exited GSK in Q2 2022, selling an estimated $29.2M.
  • Letko, Brosseau & Associates's ten largest holdings make up 35% of its $5.65B portfolio in Q2 2022.
  • Letko, Brosseau & Associates opened 3 new positions and closed 4 in Q2 2022.
  • Letko, Brosseau & Associates's portfolio value fell 16% quarter-over-quarter to $5.65B.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2022, filed 9 Aug 2022.